bluebird bio, Inc. (NASDAQ:BLUE) Files An 8-K Submission of Matters to a Vote of Security Holders

On June 20, 2018, bluebird bio, Inc. (the “Company”) held its previously announced Annual Meeting of Stockholders (the “Meeting”), at which a quorum was present.At the Meeting, the stockholders of the Company voted on the three proposals as follows: (i) John O. Agwunobi, Mary Lynne Hedley and Daniel S. Lynch as Class II members of the Board to serve until the Company’s 2021 annual meeting of stockholders (“Proposal 1”); (ii)to approve, on a non-binding advisory basis, the compensation paid to our named executive officers (“Proposal 2”); and (iii) to ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2018 (“Proposal 3”).

The Company’s stockholders re-elected the three persons listed below as Class II directors to Proposal 1. The voting results were as follows:

The Company’s stockholders approved Proposal 2 in a non-binding advisory vote.The voting results were as follows:

The Company’s stockholders approved Proposal 3.The voting results were as follows:

About bluebird bio, Inc. (NASDAQ:BLUE)
bluebird bio, Inc. is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder. Its oncology programs are built using lentiviral gene delivery and T cell engineering, with a focus on developing T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. Its oncology program, bb2121, is a CAR T cell product candidate targeting B-cell maturation antigen, or BCMA, in multiple myeloma. It also offers discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline.